XT
CRVS icon

XTX Topco’s Corvus Pharmaceuticals CRVS Stock Holding History

XTX Topco’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-34,305
Closed -$502K – 4228
2026
Q1 		$502K Buy
+34,305
New +$547K 0.01% 2051
2025
Q2 		– Sell
-14,958
Closed -$47.6K – 2496
2025
Q1 		$47.6K Sell
14,958
-42,255
-74% -$199K ﹤0.01% 2004
2024
Q4 		$306K Buy
57,213
+43,127
+306% +$322K 0.03% 1198
2024
Q3 		$74.4K Buy
+14,086
New +$50.6K 0.01% 1646
2024
Q1 		– Sell
-23,415
Closed -$41.2K – 1915
2023
Q4 		$41.2K Buy
23,415
+4,171
+22% +$6.1K 0.01% 1264
2023
Q3 		$28.1K Buy
+19,244
New +$40.7K ﹤0.01% 1342

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

XTX Topco's CRVS Position: Q2 2026 in Review

XTX Topco sold out of Corvus Pharmaceuticals (CRVS) in Q2 2026, closing a stake of 34,305 shares — an estimated $502K sold.

XTX Topco first reported a position in CRVS in Q3 2023 and held it in 6 quarters. The position peaked at $502K in Q1 2026. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • XTX Topco reported no remaining Corvus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 34,305 Corvus Pharmaceuticals shares in Q2 2026, an estimated $502K.
  • XTX Topco first reported a position in Corvus Pharmaceuticals in Q3 2023 and held it in 6 quarters.
  • XTX Topco's Corvus Pharmaceuticals position peaked at $502K in Q1 2026.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.